RESUMEN
BACKGROUND: An observational study was conducted in Maputo, Mozambique, to investigate trends in prevalence of HIV drug resistance (HIVDR) in antiretroviral (ART) naïve subjects initiating highly active antiretroviral treatment (HAART). METHODOLOGY/PRINCIPAL FINDINGS: To evaluate the pattern of drug resistance mutations (DRMs) found in adults on ART failing first-line HAART [patients with detectable viral load (VL)]. Untreated subjects [Group 1 (G1; n=99)] and 274 treated subjects with variable length of exposure to ARV´s [6-12 months, Group 2 (G2;n=93); 12-24 months, Group 3 (G3;n=81); >24 months (G4;n=100)] were enrolled. Virological and immunological failure (VF and IF) were measured based on viral load (VL) and T lymphocyte CD4+ cells (TCD4+) count and genotypic resistance was also performed. Major subtype found was C (untreated: n=66, 97,06%; treated: n=36, 91.7%). Maximum virological suppression was observed in G3, and significant differences intragroup were observed between VF and IF in G4 (p=0.022). Intergroup differences were observed between G3 and G4 for VF (p=0.023) and IF between G2 and G4 (p=0.0018). Viral suppression (<50 copies/ml) ranged from 84.9% to 90.1%, and concordant VL and DRM ranged from 25% to 57%. WHO cut-off for determining VF as given by 2010 guidelines (>5000 copies/ml) identified 50% of subjects carrying DRM compared to 100% when lower VL cut-off was used (<50 copies/ml). Length of exposure to ARVs was directly proportional to the complexity of DRM patterns. In Mozambique, VL suppression was achieved in 76% of individuals after 24 months on HAART. This is in agreement with WHO target for HIVDR prevention target (70%). CONCLUSIONS: We demonstrated that the best way to determine therapeutic failure is VL compared to CD4 counts. The rationalized use of VL testing is needed to ensure timely detection of treatment failures preventing the occurrence of TDR and new infections.
Asunto(s)
Antirretrovirales/uso terapéutico , Terapia Antirretroviral Altamente Activa , Infecciones por VIH/tratamiento farmacológico , VIH-1/efectos de los fármacos , Adulto , Instituciones de Atención Ambulatoria , Recuento de Linfocito CD4 , Farmacorresistencia Viral/genética , Femenino , Genotipo , Infecciones por VIH/epidemiología , Infecciones por VIH/virología , VIH-1/genética , VIH-1/fisiología , Interacciones Huésped-Patógeno/efectos de los fármacos , Humanos , Masculino , Mozambique/epidemiología , Mutación , Prevalencia , Factores de Tiempo , Insuficiencia del Tratamiento , Carga Viral/efectos de los fármacos , Carga Viral/genéticaRESUMEN
Background: An observational study was conducted in Maputo, Mozambique, to investigate trends in prevalence of HIV drug resistance (HIVDR) in antiretroviral (ART) naïve subjects initiating highly active antiretroviral treatment (HAART). Methodology/principal findings: To evaluate the pattern of drug resistance mutations (DRMs) found in adults on ART failing first-line HAART [patients with detectable viral load (VL)]. Untreated subjects [Group 1 (G1; n=99)] and 274 treated subjects with variable length of exposure to ARV´s [6-12 months, Group 2 (G2;n=93); 12-24 months, Group 3 (G3;n=81); >24 months (G4;n=100)] were enrolled. Virological and immunological failure (VF and IF) were measured based on viral load (VL) and T lymphocyte CD4+ cells (TCD4+) count and genotypic resistance was also performed. Major subtype found was C (untreated: n=66, 97,06%; treated: n=36, 91.7%). Maximum virological suppression was observed in G3, and significant differences intragroup were observed between VF and IF in G4 (p=0.022). Intergroup differences were observed between G3 and G4 for VF (p=0.023) and IF between G2 and G4 (p=0.0018). Viral suppression (<50 copies/ml) ranged from 84.9% to 90.1%, and concordant VL and DRM ranged from 25% to 57%. WHO cut-off for determining VF as given by 2010 guidelines (>5000 copies/ml) identified 50% of subjects carrying DRM compared to 100% when lower VL cut-off was used (<50 copies/ml). Length of exposure to ARVs was directly proportional to the complexity of DRM patterns. In Mozambique, VL suppression was achieved in 76% of individuals after 24 months on HAART. This is in agreement with WHO target for HIVDR prevention target (70%). Conclusions: We demonstrated that the best way to determine therapeutic failure is VL compared to CD4 counts. The rationalized use of VL testing is needed to ensure timely detection of treatment failures preventing the occurrence of TDR and new infections.
Asunto(s)
Humanos , Animales , Masculino , Femenino , Adulto , Infecciones por VIH/rehabilitación , VIH-1/efectos de los fármacos , Terapia Antirretroviral Altamente Activa , Antirretrovirales/uso terapéutico , Infecciones por VIH/epidemiología , Infecciones por VIH/virología , Prevalencia , VIH-1/fisiología , VIH-1/genética , Insuficiencia del Tratamiento , Recuento de Linfocito CD4 , Carga Viral/efectos de la radiación , Carga Viral/genética , Farmacorresistencia Viral , Farmacorresistencia Viral/genética , Interacciones Huésped-Patógeno , Atención Ambulatoria , Genotipo , MutaciónRESUMEN
OBJECTIVE: In Mozambique, highly active antiretroviral treatment (HAART) was introduced in 2004 followed by decentralization and expansion, resulting in a more than 20-fold increase in coverage by 2009. Implementation of HIV drug resistance threshold surveys (HIVDR-TS) is crucial in order to monitor the emergence of transmitted viral resistance, and to produce evidence-based recommendations to support antiretroviral (ARV) policy in Mozambique. METHODS: World Health Organization (WHO) methodology was used to evaluate transmitted drug resistance (TDR) in newly diagnosed HIV-1 infected pregnant women attending ante-natal clinics in Maputo and Beira to non-nucleoside reverse transcriptase inhibitors (NNRTI), nucleoside reverse transcriptase inhibitors (NRTI) and protease inhibitors (PI). Subtypes were assigned using REGA HIV-1 subtyping tool and phylogenetic trees constructed using MEGA version 5. RESULTS: Although mutations associated with resistance to all three drug were detected in these surveys, transmitted resistance was analyzed and classified as <5% in Maputo in both surveys for all three drug classes. Transmitted resistance to NNRTI in Beira in 2009 was classified between 5-15%, an increase from 2007 when no NNRTI mutations were found. All sequences clustered with subtype C. CONCLUSIONS: Our results show that the epidemic is dominated by subtype C, where the first-line option based on two NRTI and one NNRTI is still effective for treatment of HIV infection, but intermediate levels of TDR found in Beira reinforce the need for constant evaluation with continuing treatment expansion in Mozambique.
Asunto(s)
Fármacos Anti-VIH/farmacología , Farmacorresistencia Viral , Genotipo , Infecciones por VIH/virología , VIH-1/efectos de los fármacos , VIH-1/genética , Adolescente , Adulto , Fármacos Anti-VIH/uso terapéutico , Terapia Antirretroviral Altamente Activa , Farmacorresistencia Viral/genética , Femenino , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/epidemiología , VIH-1/clasificación , Humanos , Masculino , Mozambique/epidemiología , Mutación , Filogenia , Embarazo , Adulto JovenRESUMEN
Objective: InMozambique, highly active antiretroviral treatment (HAART) was introduced in 2004 followed by decentralizationandexpansion, resulting inamorethan20-fold increase incoverageby2009. ImplementationofHIV drugresistancethresholdsurveys (HIVDR-TS) iscrucial inorder tomonitor theemergenceof transmittedviral resistance, andtoproduceevidence-basedrecommendationstosupportantiretroviral (ARV)policyinMozambique. Methods: WorldHealthOrganization(WHO)methodologywasusedtoevaluatetransmitteddrugresistance(TDR) innewly diagnosedHIV-1 infectedpregnantwomenattendingante-natal clinics inMaputoandBeira tonon-nucleosidereverse transcriptaseinhibitors(NNRTI),nucleosidereversetranscriptaseinhibitors(NRTI)andproteaseinhibitors(PI).Subtypeswere assignedusingREGAHIV-1subtypingtoolandphylogenetictreesconstructedusingMEGAversion5. Results:Althoughmutations associatedwith resistance toall threedrugweredetected in these surveys, transmitted resistancewasanalyzedandclassifiedas,5%inMaputoinbothsurveysforallthreedrugclasses.Transmittedresistanceto NNRTI inBeira in2009wasclassifiedbetween515%, anincreasefrom2007whennoNNRTImutationswerefound.All sequencesclusteredwithsubtypeC. Conclusions: OurresultsshowthattheepidemicisdominatedbysubtypeC,wherethefirst-lineoptionbasedontwoNRTI andoneNNRTI isstilleffectivefor treatmentofHIVinfection,but intermediatelevelsofTDRfoundinBeirareinforcethe needforconstantevaluationwithcontinuingtreatmentexpansioninMozambique.
Asunto(s)
Humanos , Femenino , Embarazo , Infecciones por VIH/virología , VIH-1/efectos de la radiación , VIH-1/genética , Fármacos Anti-VIH/farmacología , Terapia Antirretroviral Altamente Activa , Farmacorresistencia Viral/genética , Mozambique , Filogenia , Infecciones por VIH/terapia , Infecciones por VIH/epidemiología , VIH-1/clasificación , Fármacos Anti-VIH/uso terapéutico , Mozambique/epidemiología , MutaciónRESUMEN
Background Anobservational study was conducted in Maputo, Mozambique, to investigate trends in prevalence of HIV drug resistance (HIVDR) in antiretroviral (ART) naïve subjects initiating highly active antiretroviral treatment (HAART). Methodology/Principal Findings Toevaluate the pattern of drug resistance mutations (DRMs) found in adults on ART failing first-line HAART [patients with detectable viral load (VL)]. Untreated subjects [Group 1 (G1; n=99)] and 274 treated subjects with variable length of exposure to ARV´s [612 months, Group 2(G2;n=93); 12-24 months, Group 3(G3;n=81); >24 months (G4;n=100)] were enrolled. Virological and immunological failure (VF and IF) were measured based on viral load (VL) and Tlymphocyte CD4+cells (TCD4+) count and genotypic resistance was also performed. Major subtype found was C (untreated: n=66, 97,06%; treated: n=36, 91.7%). Maximumvirological suppression was observed in G3, and significant differences intragroup were observed between VF and IF in G4 (p=0.022). Intergroup differences were observed between G3andG4forVF(p=0.023) andIFbetweenG2andG4(p=0.0018). Viral suppression (5000 copies/ml) identified 50% of subjects carrying DRM compared to 100% when lower VLcut-off was used (<50 copies/ml). Length of exposure to ARVs was directly proportional to the complexity of DRM patterns. In Mozambique, VL suppression was achieved in 76% of individuals after 24 months on HAART. This is in agreement with WHO target for HIVDR prevention target (70%). Conclusions Wedemonstratedthat the best way to determine therapeutic failure is VL compared to CD4 counts. The rationalized use of VL testing is needed to ensure timely detection of treatment failures preventing the occurrence of TDR and new infections.